A2ALL1 |
Bacterial Translocation Following Living Donor Liver Transplant: Risk of recurrent fibrosis and impact of graft size |
Theresa Lukose |
Elizabeth Verna, MD, MS |
A2ALL1 |
Chronic HEV in Liver Transplant Recipients |
Norah Terrault |
Norah Terrault |
A2ALL1 |
Genomics and Regeneration in the Transplant Setting |
Brian Conboy |
Kim Olthoff |
A2ALL1 |
proteomicgenomic signatures in the serum for the diagnosis of liver allograft rejection and recurrent HCV |
abraham shaked |
abraham shaked |
A2ALL1 |
Retained Organic Solutes and Clinical Outcomes in Hemodialysis |
Timothy W. Meyer |
Timothy W. Meyer |
A2ALL1 |
The Differential Impact of Donor-Specific Antibodies in Living vs. Deceased Donor Liver Transplantation |
Flow Laboratory, attn.: Anat Tambur |
Josh Levitsky, MD |
AALF |
Acute Liver Failure Study Group Hepatitis B-related Acute Liver Failure Serum Samples and Clinical Data |
Adrian Di Bisceglie |
Adrian Di Bisceglie |
AALF |
A microarray-based viral discovery program for indeterminate ALF |
|
Charles Chiu, MD, PhD |
AALF |
Analysis of Serum DNA fragments in Acetaminophen Overdose Patients as Damage-Associated Molecular Patterns and Potential Cause of Acute Liver Failure |
Corron Sanders |
Hartmut Jaeschke, PhD |
AALF |
Analyzing a new enzyme assay, Alpha-GST, in patients with acute liver failure |
|
William Lee |
AALF |
Analyzing a new enzyme assay, Alpha-GST, in patients with acute liver failure |
|
William M. Lee, MD |
AALF |
Apoptosis Markers in Patients with Acute Liver Failure, Who Receive Intravenous N-acetylcysteine |
Ray Chung |
Ray Chung |
AALF |
Apoptotic Hepatocyte Death |
Bishr Omary |
|
AALF |
Assessment of Isoforms of Alanine Aminotransferase in the Diagnosis of Drug-Induced Liver Injury and Acute Liver Failure |
Stacey Ruiz |
William Lee |
AALF |
Biomarker Discovery in Acute Liver Failure (ALF) |
Corron Sanders |
David Rudnick MD-PhD |
AALF |
Determination of anti-isoniazid (INH) and autoantibodies in serum from patients with severe INH-induced hepatotoxicity |
Corron Sanders |
Jack Uetrecht, M.D., Ph.D. |
AALF |
Determination of Serum Micro-RNA in ALF patients and Determination of Serum Circulating human genomic DNA level in ALF patients |
|
William Lee |
AALF |
Determine if Mutations in SH2B3 are a Cause of Autoimmune Induced Acute Liver Failure (ALF) |
Corron Sanders |
Wendy Chung, MD, PhD |
AALF |
Determining Whether the Administration of N-acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure Provides Amelioration of the Systemic Inflammatory Response |
Todd Stravitz, MD |
|
AALF |
Evaluation of the whole exome of patients with acute hepatitis B-related acute liver failure |
Corron Sanders |
Raymond Chung, MD & Veeral Ajmera, MD |
AALF |
Extension and validation of results for serum immune analytes and leukocytes infiltrating liver biopsies from the US Drug-Induced Liver Injury Network |
Angela Bowling |
Herbert Bonkovsky, MD |
AALF |
Extension and validation of results for serum immune analytes and leukocytes infiltrating liver biopsies from the
US Drug-Induced Liver Injury Network |
Angela Bowling |
Herbert Bonkovsky, MD |
AALF |
Factors Influencing the Development of Acute Renal Failure in Patients with Acetaminophen Induced Acute Liver Failure |
William Lee |
|
AALF |
Further Evaluation of the Role of Serum Acetaminophen Adducts in the Diagnosis of Acetaminophen Poisoning |
Laura James |
Laura James |
AALF |
Galectin-9 As a Predictive Biomarker in drug-induced liver failure |
Corron Sanders |
Hugo R. Rosen, MD |
AALF |
Genomewide dissection of host factors in HAV associated acute liver failure |
Corron Sanders |
Mark Seielstad, PhD |
AALF |
Hepatitis E Virus Infection in Adult American Patients with Acute Liver Failure |
Corron Sanders |
Robert Fontana, MD |
AALF |
Indeterminate and Viral Hepatitis Subjects |
Laura James |
|
AALF |
Ophthalmic Acid as an Oxidative Biomarker in Acute Liver Failure |
Corron Sanders |
Constantine Karvellas, MD, FRCPC |
AALF |
Pharmacogenetics of Acetaminophen Toxicity |
Michael Court |
Michael Court |
AALF |
Phosphatonin Study |
Nahid Attar |
Corron Sanders |
AALF |
Possible Role of Phosphatonins in the Hypophosphaternia of Acute Liver Failure |
Blake Gregory |
William Lee |
AALF |
Prognostic Value of the Ligands-RAGE Axis in Patients with Acetaminophen-induced Hepatotoxicity |
Corron Sanders |
Giuseppina Basta, DBiol |
AALF |
Role of Wnt/Beta-Catenin Signaling in Stimulation of Liver Regeneration Following Acetaminophen Induced Acute Liver Failure |
Udayan Apte |
Udayan Apte |
AALF |
Serum Apoptosis Markers as Biomarkers in Acute Liver Failure |
Anne Rutherford |
Raymond Chung |
AALF |
Serum Factors and Liver Stem Cell Response in Patients with Acute Liver Failure |
Neil Theise |
|
AALF |
Serum Levels of Arginase-1 in Acute Liver Failure |
Corron Sanders |
William M. Lee, MD |
AALF |
Serum Osteopontin Levels in Acute Liver Failure |
Praveen Srungaram, MD |
William Lee |
AALF |
The Role of Viral and Cinical Factors in Predicting the Outcomes of Patients with Hepatitis B-Related Acute Liver Failure |
Doan Y. Dao |
William Lee |
AALF |
The use of lactate dehydrogenase to predict the etiology of acute liver injury |
Corron Sanders |
Kurt Kleinschmidt |
AALF |
Transaldolase Deficiency in Acute Liver Failure |
Andras Perl |
|
AALF |
Use of Procalcitonin as a Biomarker of Bacterial Infection in Acute Liver Failure and Acute Liver Injury |
William Lee and Jody Balko |
William Lee |
AALF |
Using cell free microRNA (miRNA) as improved clinical biomarkers of drug-induced liver injury |
Corron Sanders |
Qiang Shi, PhD |
BARC |
Genetic Determinants of Biliary Atresia |
Dr. Saul Karpen |
Saul Karpen |
BARC |
Genetic Determinants of Biliary Atresia (A005) |
Jorge Bezerra |
Dr. Saul Karpen |
BARC |
Inborn Errors of Bile Acid Meatabolism Ancillary Study |
James Heubi |
Jame Heubi |
BARC |
MicroRNA in Biliary Atresia |
Joshua Friedman |
Josh Friedman |
BARC |
Role of Rotavirus in Human Billary Atresia |
Maria Clemente |
Kathleen Schwarz |
BARC |
Serum Fibrosis Markers in Biliary Atresia |
Yumi Turmelle |
|
BARC |
Strategic Targeting of Viral Genomes in Biliary Atresia |
Rosemary Nagy |
|
CKD-BIOCON |
U01DK085649/Validation of Novel CKD Biomarkers in CRIC/A112985 |
Kathleen Liu |
Kathleen Liu |
CKD-BIOCON |
U01 DK085689 Blood Biomarkers as Predictor of Ourcomes in CKD |
Vicky Makky |
Dr. Lesley Inker |
CKID |
Adiponectin in Cardiovascular Disease in CKiD Children |
Mark Mitsnefes |
Mark Mitsnefes |
CKID |
Association of apolipoprotein-1 (APOL1) genetic variants with renal disease progression and cardiovascular morbidity in African Americans |
Beth Binns and Jeffrey Kopp |
Robert Woroniecki |
CKID |
Disordered Mineral Metabolism in CKiD |
Anthony Portale |
Anthony Portale |
CKID |
Genes and Genomics of Renal Hypodysplasia in the CKiD Cohort Study |
Ali Gharavi |
Ali Gharavi, MD |
CKID |
Identifying Genetic Risk Factors for Chronic Kidney Disease in Children from Genomic Imbalances and Chromosomal Rearrangements
|
Weining Lu |
Weining Lu |
CKID |
NAMPT as a Potential Risk Factor for CKD
|
ShuiQing Ye |
ShuiQing Ye |
CKID |
Pediatric Investigation for Genetic Factors Associated with Renal Progression |
Craig Wong |
Craig Wong |
CKID |
"Prognostic Biomarkers to Predict Progression of Pediatric Chronic Kidney Disease" |
Ellen R. Brooks, Ph.D. |
Ellen R. Brooks, Ph.D. |
CKID |
Screening for Dent Diseaes Mutations in Patients with Proteinuria
|
Andrea Cogal |
John Lieske |
CKID |
Tobacco Use and Second Hand Smoke (SHS) in Children Enrolled in CKiD |
Abiodun Omoloja |
Abiodun Omoloja |
CRIC |
CKD Biomarker Consortium - Novel Biomarkers of CKD Progression |
Kathleen Liu |
Kathleen Liu |
CRIC |
Composition of Proteinuria and Progression of Chronic Kidney Disease |
Chi-yan Hsu |
Brett Chromy |
CRIC |
Transcriptome Driven Urinary Protein Markers for CKD progression |
Wenjun Ju |
Matthias Kretzler |
CRISP1 |
Copeptin and Pro-ANP as Predictors of Progression in ADPKD |
Vicente E. Torres |
James Bost |
CRISP1 |
Discovery of prognostic urine biomarkers in ADPKD using capillary electrophoresis coupled on-line to mass spectrometry (CE-MS) |
Andreas Kistler |
Andreas Kistler |
CRISP1 |
Discovery of Prognostic Urine Biomarkers in ADPKD Using Capillary Electrophoresis Coupled On-Line to Mass Spectrometry (CE-MS) |
Harald Mischack |
Andreas Kistler/Andreas Serra |
CRISP1 |
Validating Serum and Urine Biomarkers of Kidney Injury for Diagnosis and Progression of PKD |
Chiray Parikh/James Bost |
Chiray Parikh |
DAC |
Association of Genetic Polymorphism and Vascular Access Outcomes in Hemodialysis Patients |
Ivan D. Maya |
|
DILIN |
Characteristics of Hepatits C Infectious Status in the Drug-Induced Liver Injury Network |
Mary Moggio |
K. Rajender Reddy, MD |
DILIN |
Circulating liver derived mRNA as biomarkers for DILIN |
Lorraine Mehltretter |
Paul B. Watkins |
DILIN |
Hepatitis E DILIN Ancillary Study |
Ron Engle |
Ron Engle |
DILIN |
HEV Testing |
Ron Engle |
Mary Moggio |
DILIN |
MLTT Ancillary Study with Pfizer (Kawabata Ancillary Study) |
Kathy Galan |
Jim Rochon, PH.D. |
DILIN |
Pilot Study to Delineate Chemokine/cytokine Profiles and their Correlation with DILI |
Herbert L. Bonkovsky, MD |
Herbert Bonkovsky, MD |
DILIN |
Pilot study to delineate miRNA profiles and their correlation with clinical features in DILI |
Nury Steuerwald, PhD |
Herbert Bonkovsky, MD |
DILIN |
Serum Proteomics and Biomarker Discovery in Patients with Drug Induced Liver Injury (DILI) and Healthy Controls |
Naga Chalasani |
|
EDIC |
REPRO-EDIC |
Aruna Sarma/Catherine Kim |
Aruna Sarma/Catherine Kim |
FHN_DAILY |
Effect of Frequent Dialysis on Plasma Adipocytokine |
Manish Suneja |
John Stokes, Manish Suneja |
FHN_DAILY |
Effect of Frequent Dialysis on Plasma Adipocytokine |
Manish Suneja |
John Stokes, Manish Suneja |
FHN_DAILY |
ESRD Endocrinopathy and Daily Dialysis |
Joan Lo |
Joan Lo |
FHN_DAILY |
ESRD Endocrinopathy and Daily Dialysis |
Joan Lo |
Joan Lo |
FHN_DAILY |
ESRD Endocrinopathy and Daily Dialysis |
Joan Lo |
Joan Lo |
FHN_DAILY |
FHN Ancillary Biomarkers |
George A. Kaysen, MD, PhD |
George A. Kaysen, MD, PhD |
FHN_DAILY |
Frequent Hemodialysis Network Daily Dialysis Trial |
Tjien Dwyer |
George A. Kaysen, MD, PhD |
FHN_DAILY |
Pathways influencing left ventricular hypertrophy in hemodialysis patients |
George Kaysen, MD, PHD , Phone 530 752-4010 |
Christopher T. Chan MD |
FHN_DAILY |
The Effects of Daily Dialysis on Cognitive Function in End-Stage Renal Disease |
Manjula Tamura |
Manjula Tamura |
FHN_DAILY |
Uremic Solutes and Health Measures in the FHN Study |
Timothy W. Meyer |
Timothy W. Meyer |
FSGSFONT |
Alterations in Familial FSGS Genes |
Martin Pollack |
Martin Pollack |
FSGSFONT |
Biomarkers of Immunosuppressant Therapy Resistance in Primary FSGS |
Robert Woronieki, MD |
|
FSGSFONT |
Cytokine and Transcription Factor Gene Polymorphism in Steroid Resistant FSGS in Children |
Diego H. Aviles/Jovany Zabaleta |
Diego H. Aviles/Jovany Zabaleta |
FSGSFONT |
Determination of low molecular weight proteinuria and prevalence of Dent disease in patients with focal segmental glomerulosclerosis |
Lada Beara-Lasic |
John Lieske |
FSGSFONT |
FSGS Clinical Trial |
Christine Sethna |
Christine Sethna, Howard Trachtman |
FSGSFONT |
Genetic Analysis of Subjects Enrolled in the FSGS - Controlled Trial |
Jeffrey Kopp |
Jeffrey Kopp |
FSGSFONT |
Genetics in FSGS |
Lisa Guay-Woodford |
Lisa Guay-Woodford/Rong Li |
FSGSFONT |
PLCEI Mutations and New Genes in FSGS |
Friedhelm Hilderbrant |
|
FSGSFONT |
Role of Circulating Protein 1135 in the Development of FSGS |
Sumant Singh Chugh |
Sumant Singh Chugh |
FSGSFONT |
Solube Urokinase Receptor (suPAR) is a Circulating FSGS Factor |
Jochen Reiser |
Jochen Reiser, Changli Wei |
FSGSFONT |
TNFα Pathway Blockade Ameliorates Toxic Effects of FSGS Plasma on Podocyte Cytoskeleton. |
Elena Torban |
Elena Torban |
FSGSFONT |
Urinary Exosomal Transcription Factors as Diagnostic Biomarkers to Manage Corticosteroid Resistant FSGS |
Howard Trachtman/Peter Yuen |
Howard Trachtman |
FSGSFONT |
Urinary NGAL Excretion FSGS |
Howard Trachtman, MD |
|
FSGSFONT |
Urinary Synaptopodin as a Biomarker and Predictor in Patients enrolled in FSGS-CT |
Belinda Jim |
|
FSGSFONT |
WT-1 and Podocin in Urinary Exosomes of FSGS Patients |
Peter Yuen |
|
GOKIND |
The Genetic Basis of Pediatric Diabetes |
Julie Roessig |
Janelle Noble |
GOKIND |
The Genetic Basis of Pediatric Diabetes |
|
Janelle Noble |
GPCRC |
Antibody Profiles Defining Autoimmune Gastrointestinal Dysmotility (AGID) |
Cheryl Bernard |
Gianrico Farrugia |
GPCRC |
Genomic characterization of diabetic gastroparesis (AS11) |
Irene Sarosiek |
Irene Sarosiek |
GPCRC |
Molecular Correlates of Gastroparesis: A Hypothesis-Generating Study |
Pankaj Jay Pasricha |
Pankaj Jay Pasricha |
GPCRC |
Polymorphism of the (GT)n repeat in heme oxygenase-1 promoter in diabetic gastroparesis |
Gianrico Farrugia |
Gianrico Farrugia |
HALT_PKD_A |
FGF-23 and Vitamin D in ADPKD Patients |
Berenice Reed Gitomer |
Michel Chonchol, Robert Schrier, Berenice Reed-Gitomer |
HALT_PKD_A |
Mutation Screening of the PKD2 and PKD2 Genes in the HALT Population |
Peter Harris |
|
HEMO |
Vitamin D and Clinical Outcomes in Chronic Hemodialysis Patients |
Michel Chonchol |
|
HFMC |
Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation |
Bryan Kestenbaum |
Bryan Kestenbaum |
HFMC |
MIneral Metabolism Disturbances and AV fistula Maturation |
Bryan Kestenbaum |
Bryan Kestenbaum |
LABS |
Melanocortine-4 Receptor Mutations and Bariatric Surgery Outcome |
Christian Vaisse |
Christian Vaisse |
LABS |
Molecular Genetic Analysis of Human Obesity (R01-DK52431-15) |
Rudy Leibel |
Rudy Leibel |
LABS |
Psychosocial Changes Associated with Weight Loss |
Jacque Spitzer |
Dr. David Sarwer |
LABS |
Teen-LABS ARRA 3 Adult serum analysis |
Rosemary Miller |
Thomas Inge, MD, PhD |
LOGIC |
Genetic Modifiers of Liver Disease Severity in Alagille Syndrome |
Nancy Spinner |
Nancy Spinner |
LOGIC |
Histological and genetic analysis of patients with BAD enrolled in ChiLDREN
|
John Mage |
Jame Heubi |
LOGIC |
The Genetic Basis of Pediatric Cholestasis |
Laura Bull |
Laura Bull and Richard Thompson |
NASH |
Adipocyte-Related Genomic Determinants of Nonalcoholic Fatty Liver Disease |
Nathan Bass/Kiran Bambha |
Nathan Bass/Kiran Bambha |
NASH |
Analysis of SNPS Associated with Metabolic or Inflammatory Disease for Association to NAFLD |
Elizabeth Speliotes, MD, PhD, MPH |
Elizabeth Speliotes |
NASH |
AS036: The Intestinal Microbiome in the Development and Progression of NAFLD |
Mary Holtz |
Nita Salzman, MD, PhD |
NASH |
AS073:SOMAmer Proteomic Technology to Validate Protein Biomarkers of NASH |
Malti Nikrad |
Malti Nikrad, PhD |
NASH |
CYF 4F2 Genetic Polymorphism and Histological Response to Vitamin E in Adults and Children who participated in PIVENS and TONIC clinical trials (AS066) |
Naga Chalasani |
Naga Chalasani |
NASH |
Fructokinase (KHK) Polymorphisms as a Genetic Risk Factor for NASH |
Manal Abdelmalek |
Manal Abdelmalek |
NASH |
Genetic Determinants for NAFLD Features in Hispanic Boys: A Pilot GWAS and Pathway Bioinformatics Approach |
Joel Lavine |
Joel Lavine, MDPhD |
NASH |
Genetic Determinants for Nonalcoholic Steatohepatitis and Fibrosis: a Pilot Genome Wide Association and Pathway Bioinformatics Approach |
Naga Chalasani/Ida Cheng |
Naga Chalasani |
NASH |
Genetic Dissection of NASH |
Bradley Aouizerat |
|
NASH |
Genetics of Fatty Liver in Children |
T. Jake Liange/Arun Sanyal |
T. Jake Liange |
NASH |
Genetics of Pediatric NAFLD |
Jeffrey Schwimmer |
|
NASH |
GOALS |
James Tonascia |
|
NASH |
Hepatic Nuclear Hormone Receptor Expression in NAFLD |
Joel Lavine |
|
NASH |
Hormonal Influences on Pediatric NASH Patterns |
Kathleen Viveiros |
|
NASH |
In Vivo Non-Invasive Assessment of Hepatocyte Apoptosis in NAFLD |
Ariel Feldstein |
|
NASH |
Metabolomics and NAFLD |
Anna Mae Diehl |
|
NASH |
Non-invasive biomarkers of disease activity and fibrosis in PIVENS and TONIC (AS063) |
Naga Chalasani |
Naga Chalasani |
NASH |
Relationship between Vitamin D Status and NAFLD in Children |
Ann Scheimann |
Ann Scheimann |
NASH |
The Genetics of Non-alcoholic Fatty Liver Disease |
T. Jake Liang, M.D. |
T. Jake Liange |
NASH |
The Influence of Race and Ethnicity on the Clinical and Genetic Epidemiology of NAFLD |
Kiran Bambha, MD |
|
NASH |
The relationship between serum vitamin D levels, NASH diagnosis, and NAFLD activity score (NAS) |
James Nelson |
Kris Kowdley |
NASH |
The Relationship of Hepatic Iron Phenotype, Serum Ferritin Levels and NASH Pathogenesis (NASH CRN Ancillary Study AS040) |
Kris Kowdley |
James Nelson |
NASH |
Unbound FFA Metabolomics in NASH Patients |
Alan Kleinfeld |
|
NASH |
Use of Hyaluronic Acid (HA), Syndecan 1, YKL-40 and Alpha-2-Macroglobulin (A2M) as Non-Invasive Markers, Alone and in Combination, as Liver Fibrosis Biomarkers to Develop a Non-Invasive, Predictive Model for Liver Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients |
Denice Taylor |
|
PALF |
Determine the Prevalence of Neonatal Hemochromatosis (NH) Among Young Infants Registered in PALF (Pediatric Acute Liver Failure) by Testing Available Sera for NH Associated IgG Antibody |
Susan Kelly |
Peter Whitington |
PALF |
Discovery of Novel Human Hepatitis Viruses |
Rachel Presti |
Rachel Presti |
PALF |
Mechanisms of Hepatocellular Death in Children with Acute Liver Failure of Indeterminate Aetiology |
Anil Dhawan |
|
PALF |
Serum Amino Acid |
Lori R. Holtz |
Lori R. Holtz |
PALF |
Supplementary Testing |
Robert H. Squires, Jr. |
Robert H. Squires, Jr. |
PALF |
Thyroid Autoantibodies in the PEDS-C Trial |
Yaron Tomer |
|
PEDS-C |
Autoantibodies to CYP2E1 in children with hepatitis C. |
Dolores Njoku |
Dolores Njoku |
PEDS-C |
Autoantibody PEDS-C Study |
Lynn Burek/Monica V. Talor |
Lynn Burek/Monica V. Talor |
PEDS-C |
Effect of Hepatitis C on Adiponectin Levels in Children |
David Healy/Donna Lee Destouche |
David Healy/Donna Lee Destouche |
PEDS-C |
Effect of Hepatitis C on Adiponectin Levels in Children |
Aymin Delgado |
Aymin Delgado |
PEDS-C |
Thyroid Autoantibodies in the PEDS C Trial |
Yaron Tomer |
Yaron Tomer |
PEDS-C |
Utility of a Proteomic Profile for Predicting Sustained Virologic Response to Peginterferon/Ribavirin in Children with Chronic Hepatitis C Infection |
John McHutchison |
John McHutchison |
PEDS-C |
Viral Kinetics |
Alexandra Valsamakis |
Alexandra Valsamakis |
PROBE |
Genetic Susceptibility to Biliary Atresia |
Nancy Spinner |
Nancy Spinner |
PROBE |
Hedgehog activation and osteopontin expression as markers of fibrogenesis in biliary atresia |
John Magee |
Peter Whitington, MD |
PROBE |
Hepatic hilar lymph node histology at the time of Kasai procedure |
John Magee |
Kevin E. Bove MD |
PROBE |
IL8 and Th2 cytokines in biliary atresia |
John Magee, PI ChilDREN DCC |
Jorge Bezerra, MD |
PROBE |
Molecular Basis of Phenotypes and Clinical Outcomes in Biliary Atresia |
Jorge Bezerra |
Jorge Bezerra |
RIVUR_RIVUR |
Careful UTI Evaluation (CUTIE) |
Katie Tremont |
|
RIVUR_RIVUR |
DNA Copy Number Variations in Vesicoureteral Reflux and its Sequelae |
Dr. John Manak |
John Manak/David Hains |
RIVUR_RIVUR |
DNA Copy Number Variations in Vesicoureteral Reflux and its Sequelae |
David Hains |
David Hains/John Manek |
RIVUR_RIVUR |
Risk Factors for Renal Scarring in Children with Recurrent Urinary Tract Infection |
Katie Tremont |
|
SIGT |
Proteomics Methods for Detecting Pre-Diabetes and Diabetes |
Salvatore Sechi |
|
TEEN-LABS |
Identifying Frequency and Mutation Spectrum of Genes Mediating Susceptibility to Obesity in the Teen LABS Cohort |
Wendy Chung |
Wendy Chung and Rudolph Leibel |
TN01-NH |
Decline in anti-idiotypic antibody levels as a characteristic of the development of T1D |
Christiane Hampe, PhD |
Christiane Hampe, PhD |
TN01-NH |
Detection of beta cell death in the TrialNet natural history study |
Kevan Herold, MD |
Kevan Herold, MD |
TN01-NH |
Exploring Serum MicroRNAs as Novel Biomarkers of Type 1 Diabetes |
Alberto Pugliese |
Alberto Pugliese, MD |
TN01-NH |
Innate and adapative immune responses in subjects at risk for T1D |
Kevan Herold |
Kevan Herold, MD |
TN01-NH |
Pilot Study for Evaluation of ECL-IAA |
Liping Yu, MD |
Liping Yu, MD |
TN01-NH |
Request for Samples for Gene Expression Profiling |
Jeffrey Bluestone |
|
TN01-NH |
Serum Biomarkers to Detect Beta Cell Stress in Early Type 1 Diabetes |
Linda DiMeglio, MD, MPH |
Linda DiMeglio, MD, MPH |
TN02-MMFDZB |
Analysis of beta cell death in control subjects in the MMF/DZB TrialNet study |
Kevan Herold, MD |
Kevan Herold, MD |
TN05-ANTICD20 |
Phenotypic and genetic characterization of human autoreactive B cells in T1D |
Eric Meffre, MD |
Eric Meffre, MD |
TN05-ANTICD20 |
Rituximab for treatment of Type 1 diabetes: Impact on JC viral replication |
Vicky Slunaker, Grants Manager |
Eric Wiebke, MD (Ship samples to Co-I, Adriana Weinberg, MD) |
TN08-GAD-NEW-ONSET |
The effects of GAD immunization on the T cell repertoir |
Helena Reijonen |
Helena Reijonen |
TN14-ANTI-IL-1-BETA |
Serum Signature Analysis of participants of the TrialNet Canakinumab (TNC) Trial |
Martin Hessner, PhD |
Martin Hessner, PhD |
TRIALNET |
B cell function and phenotype as predictors of therapeutic response to ritixumab |
David J. Rawlings, MD |
David J. Rawlings, MD |
TRIALNET |
Biomarkers for the loss of immune homeostasis in children with newly diagnosed type 1 diabetes |
Marty Eldridge / Joanna Davies, PhD |
Joanna Davies, PhD |
TRIALNET |
Novel Biomarkers and ImmunoChip Analysis in Type 1 Diabetes |
Suna Onengut-Gumuscu, PhD |
Stephen S. Rich, PhD |
TRIALNET |
Novel Biomarkers and ImmunoChip
Analysis in Type 1 Diabetes |
Massimo Pietropaolo, MD |
Massimo Pietropaolo, MD |
TRIALNET |
Prospective analyses of novel autoantigen epitopes in prediabetes and the honeymoon period |
Janet Wenzlau, PhD |
Howard Davidson, PhD |
TRIALNET |
Prospective analyses of novel autoantigen epitopes in prediabetes and the honeymoon period |
Katherine Gray, Asst to John Hutton |
John Hutton, PhD |
TRIALNET |
Role of IL-17 in the natural history of type 1 diabetes |
Ash Marwaha, PhD |
Rusung Tan, MD, PhD |
TRIALNET |
Serum Signatures in T1D |
Martin Hessner |
Martin J. Hessner, PhD |
TRIALNET |
Understanding regulatory defects in T1D: natural history and impact of therapy |
|
Jane Buckner |
VIRAHEP-C |
CD 8 T cell study |
Jared Klarquist |
|
VIRAHEP-C |
Host Genomics and Hepatitis-C Outcomes and Host Genetic Determinants of Steotosis and Insulin Resistance in Chronic Hepatitis C |
Leland Yee |
|
VIRAHEP-C |
Immunoglobulin Allotypes and Response Rates to Antiviral Therapy for Hepatitis C |
Janardan P. Pandey |
Janardan P. Pandey |
VIRAHEP-C |
Patient Genetics |
Shannon Rhodes |
|
VIRAHEP-C |
Predictors of Response to Peginterferon and Ribavirin in the VIRAHEP-C Cohort: Interaction of Serum IP-10 and IL28b Genotype |
Michael Fried |
|
VIRAHEP-C |
Ribavirin Pharmacokinetics in African Americans and Caucasians Infected with HCV Genotype 1 |
Tom Dowling |
|
VIRAHEP-C |
Viral genetics study |
John Travis |
|